VivoSeq
Other

Hemosiderosis

4

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Hemosiderosis is an early-stage landscape with 4 programs across 2 companies. The most active players are Sanofi, Novartis. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

75/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 1Novartis logo

Novartis

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

6

clinical trials

Completed3 · 50%
Unknown status1 · 17%
Withdrawn1 · 17%
Recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Leflunomide for Idiopathic Pulmonary Hemosiderosis in Children
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1/2·NCT05937191·34 enrolled
Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis
Completed·Novartis logoNovartis·Phase 4·NCT03372083·44 enrolled
Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox
Completed·Novartis logoNovartis·N/A·NCT01394029·120 enrolled
Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional Hemosiderosis
Completed·Novartis logoNovartis·Phase 2·NCT00631163·102 enrolled
Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis
Withdrawn·—·N/A·NCT02664571
Efficacy of Bone Marrow Mesenchymal Stem Cell in Pulmonary Hemosiderosis
Unknown status·SSun Yat-sen University·Phase 1·NCT02985346·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)